Therapy News and Research

RSS

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference.

15 Jun 2012

Osiris receives consent from NZ to market Prochymal for GvHD

Osiris Therapeutics, Inc., announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

15 Jun 2012

FDA clears KCI’s V.A.C.Therapy System

Kinetic Concepts, Inc. announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) to market its proprietary Vacuum Assisted Closure, or V.A.C. Therapy System, for the management of closed surgical incisions.

15 Jun 2012

Study reveals molecular link between aging and cancer

It has long been known that cancer is a disease of aging, but a molecular link between the two has remained elusive.

15 Jun 2012

Sanovas receives U.S. patent allowance for microsurgical lung cancer technology

Sanovas, Inc., a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its first patent relating to systems and methods for the removal of unwanted biological material, such as tissue growths and tumors, in hard-to-reach bodily cavities.

15 Jun 2012

Study strengthens link between HHV-6B and mesial temporal lobe epilepsy

A ten-year NIH-funded study has determined that a third of infants with prolonged seizures and fever suffer from either a new or reactivated roseola virus infection. Roseola viruses are the cause of the common childhood rash, but can also cause limbic encephalitis, a condition that frequently progresses to epilepsy. Investigators discovered one of the roseola viruses, human herpesvirus-6B (HHV-6B) in the blood of 32% of 169 infants with prolonged seizures, a condition known as status epilepticus.

15 Jun 2012

High-efficiency oxygen inhaler from Dehaier

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its "High-Efficiency Oxygen Inhaler" with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China.

15 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012

New scientific findings in anticoagulation for stroke prevention

New scientific findings in anticoagulation for stroke prevention are paving the way for updates to the European Society of Cardiology (ESC) Guidelines for the management of atrial fibrillation.

14 Jun 2012

Acute levodopa may worsen motor plasticity in late-stage PD

Administering acute doses of levodopa appears to worsen motor cortex plasticity as Parkinson’s disease advances, researchers report.

14 Jun 2012

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.

14 Jun 2012

Dark chocolate cuts CV risk in metabolic syndrome

Eating dark chocolate on a daily basis appears to decrease risk for cardiovascular events in patients with the metabolic syndrome, say researchers.

14 Jun 2012

ABL to perform process development and cGMP manufacturing of recombinant scuPA

Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

USPTO issues patent to Aeris’ cross-linked polymers for treatment of emphysema

Aeris Therapeutics, LLC announced that the U.S. Patent and Trademark Office has issued a patent covering the use of cross-linked polymers administered into the lung to reduce lung volume for the treatment of emphysema.

14 Jun 2012

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

14 Jun 2012

Georgia Tech startup to create new delivery method for cell-based therapies

Cell-based therapies have yet to reach their full potential in repairing damaged tissue because of the hostile environment the cells face once injected into the body. A patient's inflammatory response normally causes the majority of these therapeutic cells to die or migrate away from the area in need of repair.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.

14 Jun 2012

EvaluatePharma releases World Preview 2018 report

EvaluatePharma, the premier provider of pharmaceutical and biotech analysis including consensus forecasts, today released its World Preview 2018 report, providing an in-depth look at how the patent cliff will reshape the drug industry over the next six years — with valuable insight into which companies and products will come out as winners.

14 Jun 2012